9803539-7

11055 copy

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C07D 473/18, 473/32, 473/00, A61K 31/52 — A1

(11) International Publication Number: WO 97/30051

(43) International Publication Date: 21 August 1997 (21.08.97)

(21) International Application Number: PCT/SE97/00241

(22) International Filing Date: 14 February 1997 (14.02.97)

(30) Priority Data:
9600613-5 16 February 1996 (16.02.96) SE
9600614-3 16 February 1996 (16.02.96) SE

(71) Applicant: MEDIVIR AB [SE/SE]; Lunastigen 7, S-141 44 Huddinge (SE).

(72) Inventors: ENGELHARDT, Per; Brännkyrkagatan 90, 1tr, S-117 26 Stockholm (SE). HÖGBERG, Marita; Vårvägen 3, S-146 52 Tullinge (SE). ZHOU, Xiao-Xiong; Kallkärrsvägen 12, S-141 41 Huddinge (SE). LINDBORG, Björn; Ullstaborg, S-640 50 Björnlunda (SE). JOHANSSON, Nils, Gunnar; Bäverstigen 19, S-150 23 Enhörna (SE).

(74) Agent: MORRISON, Iain; Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published


With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: ACYCLIC NUCLEOSIDE DERIVATIVES

(57) Abstract

Compounds of formula (I) where one of R_1 and R_2 is -C(O)CH(CH(CH$_3$)$_2$)NH$_2$ or -C(O)CH(CH(CH$_3$)CH$_2$CH$_3$)NH$_2$; the other of R_1 and R_2 is -C(=O)C$_3$-C$_{21}$ saturated or monounsaturated, optionally substituted alkyl; and R_3 is OH or H; and pharmaceutically acceptable salts thereof have utility as enhanced bioavailability antivirals against herpes and retroviral infections.



(I)